Helping people breathe easy and sleep properly are the core of Sunovion. The company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Among its marketed products are asthma drug Xopenex, insomnia therapy Lunesta, schizophrenia treatment Latuda, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sunovion markets its products to primary care physicians and some specialists in the US. Sunovion is a subsidiary of Japanese firm Dainippon Sumitomo Pharma (DSP).
Sales and Marketing
Sunovion markets its products to primary care doctors and such specialists as allergists and sleep doctors. Its main customers are drug wholesalers McKesson, Cardinal Health, and AmerisourceBergen; the company also sells directly to pharmacy chains and home health care firms.
Though Sunovion traces its roots back to 1984, the company only reached profitability in 2005, the year it introduced Lunesta. Each year Lunesta became more important to the company's sales, and by 2009 accounted for about half of its revenue. Its plan is to expand the marketing of Lunesta outside of North America. The 2009 acquisition of Sunovion by DSP should help spur Asian growth efforts for Lunesta and other products, and the company had already been pursuing regulatory approval for Lunesta in international markets through partnerships with other drugmakers.
To ensure its long-term success, Sunovion also develops new drugs (and improves on already-marketed ones) in its focus areas of respiratory disease and CNS disorders. Drug candidates in the works include possible treatments for depression and anxiety. In 2011 it began marketing Latuda, which treats schizophrenia, in the US and Puerto Rico.
▲ Show Less▼ Show Full Description
Mergers and Acquisitions
Sunovion strengthened its respiratory product offerings with the late 2012 purchase of Elevation Pharmaceuticals, which has been renamed Sunovion Respiratory Development. It paid $100 million (and agreed to milestone payments of up to $330 million) for the firm, which is developing a treatment for moderate to severe COPD.